ATAI Life Sciences N.V. financial data

Symbol
ATAI on Nasdaq
Industry
Pharmaceutical Preparations
Location
Wallstrasse 16, Berlin, Germany
State of incorporation
Netherlands
Fiscal year end
December 31
Former names
ATAI Life Sciences B.V. (to 6/21/2021)
Latest financial report
10-Q/A - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 739 % -43.5%
Debt-to-equity 24.8 % +54%
Return On Equity -65.8 % -143%
Return On Assets -52.7 % -126%
Operating Margin -32K % +17.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 168M shares +1.08%
Common Stock, Shares, Outstanding 168M shares +1.09%
Entity Public Float 203M USD -50.5%
Common Stock, Value, Issued 18.8M USD +1.07%
Weighted Average Number of Shares Outstanding, Basic 161M shares +3.1%
Weighted Average Number of Shares Outstanding, Diluted 161M shares -9.54%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 331K USD -1.19%
General and Administrative Expense 55.6M USD -7.09%
Operating Income (Loss) -106M USD +18.1%
Nonoperating Income (Expense) -21.6M USD -131%
Income Tax Expense (Benefit) 265K USD -96%
Net Income (Loss) Attributable to Parent -129M USD -92.1%
Earnings Per Share, Basic -0.8 USD/shares -90.5%
Earnings Per Share, Diluted -0.77 USD/shares -71.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 30M USD -60.8%
Other Assets, Current 919K USD +44%
Assets, Current 114M USD -47.1%
Other Long-term Investments 33.9M USD +826%
Property, Plant and Equipment, Net 865K USD -12.8%
Operating Lease, Right-of-Use Asset 1.03M USD -18%
Other Assets, Noncurrent 2.43M USD -21.9%
Assets 198M USD -35.9%
Accounts Payable, Current 4.88M USD -11.4%
Accrued Liabilities, Current 12M USD -8.11%
Liabilities, Current 19.6M USD -0.26%
Operating Lease, Liability, Noncurrent 808K USD -20.1%
Other Liabilities, Noncurrent 8.38M USD +206%
Liabilities 51.2M USD +28.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -20.2M USD -5.48%
Retained Earnings (Accumulated Deficit) -661M USD -24.1%
Stockholders' Equity Attributable to Parent 146M USD -45.3%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 146M USD -45.5%
Liabilities and Equity 198M USD -35.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -22.6M USD -6.93%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 11.5M USD -28.4%
Common Stock, Shares Authorized 750M shares 0%
Common Stock, Shares, Issued 168M shares +1.09%
Common Stock, Par or Stated Value Per Share 0.11 USD/shares -8.33%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -11.2M USD -136%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 45M USD -41.2%
Interest Paid, Excluding Capitalized Interest, Operating Activities 629K USD +39.2%
Deferred Tax Assets, Valuation Allowance 90M USD -5.97%
Deferred Tax Assets, Gross 121M USD +19.5%
Operating Lease, Liability 1.07M USD -18.3%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -130M USD -115%
Operating Lease, Liability, Current 257K USD -12%
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure 0%
Unrecognized Tax Benefits 369K USD
Additional Paid in Capital 808M USD +1.11%
Depreciation, Depletion and Amortization 83K USD +27.7%
Deferred Tax Assets, Net of Valuation Allowance 30.8M USD +473%
Interest Expense 2.77M USD +25.5%